Abstract
Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radioresistance of prostate cancer cells is a practical limitation of radiotherapy. The identification of molecular targets of radioresistance in prostate cancer is important to improve therapeutic intervention. The aim of this review is to give more biological insight into some well known processes involved in radioresistance of prostate cancer especially Apoptotic pathway; DNA damage response; and NF-κB(nuclear factor kappalight- chain-enhancer of activated B cells) signaling pathway. This review integrates salient, published, research findings with underlying molecular mechanisms, preclinical efficacy, and potential clinical applications of combining radiotherapy with these molecular targeted agents for the treatment of prostate cancer.
Keywords: Prostate cancer, radiotherapy, radiosensitization
Current Pharmaceutical Design
Title:Targeted Radiosensitization in Prostate Cancer
Volume: 19 Issue: 15
Author(s): Veerander P.S. Ghotra, Albert A. Geldof and Erik H.J. Danen
Affiliation:
Keywords: Prostate cancer, radiotherapy, radiosensitization
Abstract: Radiotherapy is one of the treatment options for locally or regionally advanced prostate cancer, but radioresistance of prostate cancer cells is a practical limitation of radiotherapy. The identification of molecular targets of radioresistance in prostate cancer is important to improve therapeutic intervention. The aim of this review is to give more biological insight into some well known processes involved in radioresistance of prostate cancer especially Apoptotic pathway; DNA damage response; and NF-κB(nuclear factor kappalight- chain-enhancer of activated B cells) signaling pathway. This review integrates salient, published, research findings with underlying molecular mechanisms, preclinical efficacy, and potential clinical applications of combining radiotherapy with these molecular targeted agents for the treatment of prostate cancer.
Export Options
About this article
Cite this article as:
P.S. Ghotra Veerander, A. Geldof Albert and H.J. Danen Erik, Targeted Radiosensitization in Prostate Cancer, Current Pharmaceutical Design 2013; 19(15) . https://dx.doi.org/10.2174/1381612811319150017
DOI https://dx.doi.org/10.2174/1381612811319150017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment
Current Pharmaceutical Design Preface
Current Pharmaceutical Design Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Approaches for the Cure of Type 1 Diabetes by Cellular and Gene Therapy
Current Gene Therapy Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology Synthetic Lethality: From Research to Precision Cancer Nanomedicine
Current Cancer Drug Targets The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Kinase Inhibitors in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Pitx2 Expression Promotes p21 Expression and Cell Cycle Exit in Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Exosomes: A Novel Therapeutic Paradigm for the Treatment of Depression
Current Drug Targets Tumor Markers: The Potential of “Omics” Approach
Current Molecular Medicine